OXY

Occidental Petroleum

$53.90

+0.17%
Nov 20, 2026
Bobby Quantitative Model
Occidental Petroleum is an independent exploration and production company operating across the United States, Latin America, and the Middle East, with roughly 4.6 billion barrels of proved reserves and net production of about 1.4 million barrels of oil equivalent per day, weighted roughly 74% toward oil and natural gas liquids. It is a large-cap pure-play E&P with a differentiated midstream and petrochemicals footprint, historically anchored by the OxyChem chemicals business and a legacy of aggressive acquisition-driven growth (most notably Anadarko), which left it with a heavier debt load than many peers. The current investor narrative centers on deleveraging and portfolio simplification: the roughly $9.7 billion sale of the chemicals unit to Berkshire Hathaway has been used to pay down debt, and Q3 2026 results beat across oil & gas and midstream, reinforcing the balance-sheet repair story. That constructive narrative is being tested by a sharp late-2026 pullback in the shares and by analyst expectations of a meaningful profit decline next year as the oil price windfall from a geopolitical supply shock fades.

People also watch

ConocoPhillips

ConocoPhillips

COP

Analysis
EOG Resources

EOG Resources

EOG

Analysis
Diamondback Energy

Diamondback Energy

FANG

Analysis
Devon Energy

Devon Energy

DVN

Analysis
EQT

EQT

EQT

Analysis

BobbyInvestment Opinion: Should I buy OXY Today?

Rating: Hold, with a constructive bias. The core thesis is that OXY is a cheap-on-forward-earnings, deleveraging E&P whose 14.29% one-month collapse has pushed the price to $53.76 against an analyst average target of $71.11 (32.3% implied upside) and a consensus 'buy' headline, but the 2.29 recommendation mean with 17 of 27 analysts at Hold and an expected ~32% profit decline in 2027 mean the market is pricing a cyclical plateau, not a growth story. In short, the balance sheet is healing faster than the earnings base is growing, and that gap is what investors are being paid to underwrite.

Supporting evidence is genuinely mixed but tilts modestly positive on valuation. The stock trades at 10.31x forward EPS of $5.23 versus 24.33x trailing, a ~58% compression, and at 1.11x book versus a historical 1.3-1.9x band, while EV/EBITDA of 5.37x is consistent with a mature producer rather than a distressed one. Deleveraging is real: debt-to-equity has fallen to 0.665 from ~0.79 at end-2024, Q3 2026 alone retired $1.819 billion of debt funded partly by the $9.7 billion chemicals sale, and trailing free cash flow of $6.705 billion comfortably covers $1.257 billion of quarterly capex and $432 million of dividends. Q3 2026 delivered $1.806 billion of net income on a 26.67% net margin and 62.85% EBITDA margin with revenue up 2.23% year over year, and the 3.97% yield with a 0.149 beta makes the stock a low-correlation income holding. The counterweight is that quarterly net income has fallen from $3.345 billion in Q1 to $2.977 billion in Q2 to $1.806 billion in Q3, trailing net margin is only 10.97%, and consensus 2027 revenue of ~$25.33 billion implies no growth.

The rating would upgrade to Buy on a decisive stabilization above the $64-67 resistance zone accompanied by crude prices holding well enough to protect the $5.23 forward EPS, or if debt-to-equity pushes below ~0.55 while the dividend remains covered. It would downgrade to Sell if 2027 EPS estimates are cut toward the $4.75 low end (which would push the forward multiple toward ~11.3x on a lower earnings base and stall deleveraging), if the current ratio of 0.936 deteriorates further, or if the price breaks below the $47.94 July trough, which would open the door to the $38.80 52-week low. Net verdict: fairly valued to modestly undervalued relative to its own history and the Street's targets, but not a compelling risk/reward until crude and the share price both stabilize — the apparent cheapness is entirely contingent on forward estimates being met.

Sign up to view all

OXY 12-Month Price Forecast

The forward-looking picture is a tug-of-war between a genuinely cheap forward multiple and an earnings base that consensus expects to shrink roughly 32% next year. The bull case is anchored by balance-sheet repair — debt-to-equity at 0.665, $1.819 billion of Q3 debt retirement, and $6.705 billion of trailing free cash flow — plus a Street average target of $71.11 that sits 32.3% above the current $53.76 with no Sell ratings anywhere in coverage. The bear case is that the $5.23 forward EPS is a windfall artifact: quarterly net income has already fallen from $3.345 billion in Q1 to $1.806 billion in Q3, trailing net margin is just 10.97%, and a 0.936 current ratio leaves thin cushion if crude weakens. With the stock 20.3% below its $67.45 high and below the $64.17 October peak, the risk/reward is balanced rather than compelling, which is why the stance is neutral rather than bullish despite the headline 'buy' consensus. I would upgrade to bullish on a sustained move above $64-67 with crude holding the forward EPS intact, and downgrade to bearish on a break below the $47.94 July trough or a cut to 2027 estimates toward $4.75.

Historical Price
Current Price $53.90
Average Target $65.56
High Target $83.00
Low Target $38.80

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Occidental Petroleum's 12-month outlook, with a consensus price target around $71.11 and implied upside of +31.9% versus the current price.

Average Target

$71.11

28 analysts

Implied Upside

+31.9%

vs. current price

Analyst Count

28

covering this stock

Price Range

$60 - $83

Analyst target range

Buy
11 (39%)
Hold
17 (61%)
Sell
0 (0%)

Coverage is broad, with 27 analysts and a distribution of 11 Buy, 17 Hold, and 0 Sell, producing a consensus recommendation of "buy" but a recommendation mean of 2.29 that leans closer to neutral. The average target price is $71.11, which implies roughly 32.3% upside from the current $53.76 — a notable gap given the stock's recent 14.29% one-month decline. The bullish tilt in the headline rating is tempered by the Hold-heavy distribution, suggesting most analysts see fair value rather than compelling upside at current levels.

The target range of $60.00 to $83.00 is wide, spanning about 38% of the midpoint, which signals meaningful uncertainty about oil prices and the post-divestiture earnings base. The low end of $60 still sits 11.6% above the current price, implying that even the most cautious analyst sees the recent selloff as overdone, while the $83 high assumes a sustained oil price recovery and successful deleveraging. Institutional actions are mixed but recently constructive: Goldman Sachs upgraded to Buy from Neutral on October 1, 2026, and Wells Fargo, Susquehanna, and Stephens maintain Overweight/Positive ratings, while Morgan Stanley, Truist, and UBS remain at Equal Weight/Hold/Neutral. The absence of any Sell ratings and the clustering of targets above the market price suggest the Street views the pullback as a buying opportunity, though the wide spread and Hold-heavy consensus argue for position sizing that respects commodity-price risk.

Drowning in data?

Find the real signal!

Bulls vs Bears: OXY Investment Factors

The bear case currently has slightly stronger near-term evidence: earnings are compressing quarter over quarter, the stock has broken down 14.29% in a month with -9.56 points of relative underperformance versus SPY, and analysts explicitly model a ~32% profit decline next year. The bull case rests on valuation and balance-sheet repair — a 10.31x forward PE, 1.11x book, 3.97% yield, and $1.819 billion of Q3 debt repayment — plus a Street average target of $71.11 that implies 32.3% upside with zero Sell ratings. The single most important tension is whether the $5.23 forward EPS is achievable: if oil prices hold and estimates are met, the apparent cheapness is real and the pullback is a buying opportunity; if crude weakens and estimates are cut, the forward PE re-rates higher and the 'cheap' thesis evaporates. Until the price stabilizes above the $48 July trough, the risk/reward is balanced rather than compelling.

Bullish

  • Forward PE of 10.3x looks cheap: OXY trades at 24.33x trailing earnings but just 10.31x forward earnings, a roughly 58% compression that implies the market expects earnings to normalize sharply higher. If the $5.23 consensus EPS materializes, the stock is inexpensive on a forward basis, and the 1.11x price-to-book sits at the low end of its historical 1.3-1.9x band.
  • Analyst targets imply 32% upside: The average target price of $71.11 implies roughly 32.3% upside from the current $53.76, and even the lowest target of $60.00 sits 11.6% above the market price. With 11 Buy ratings, 17 Holds, and zero Sells, the Street broadly views the recent selloff as overdone rather than a structural breakdown.
  • Deleveraging is accelerating: Debt-to-equity has fallen to 0.665 from roughly 0.79 at the end of 2024, and Q3 2026 alone saw $1.819 billion of debt repayment, funded in part by the $9.7 billion chemicals sale to Berkshire Hathaway. Free cash flow of $2.415 billion in Q3 and $6.705 billion trailing provides the fuel to keep reducing leverage.
  • Q3 2026 beat across segments: Q3 2026 net income of $1.806 billion on a 26.67% net margin and 62.85% EBITDA margin beat across oil & gas and midstream, with revenue up 2.23% year over year to $6.772 billion. The oil & gas segment generated $6.625 billion, confirming the upstream base is performing.

Bearish

  • Earnings expected to fall ~32% next year: Analysts expect a roughly 32% profit drop in 2027 as the geopolitical oil supply shock windfall fades, and consensus 2027 revenue of about $25.33 billion implies a cyclical plateau rather than growth. Quarterly net income has already compressed from $3.345 billion in Q1 2026 to $2.977 billion in Q2 to $1.806 billion in Q3.
  • Sharp momentum breakdown: The stock is down 14.29% over the past month and 12.61% over three months, versus a still-positive 26.43% one-year return, and it fell 4.88% on the latest session alone on 13.0 million shares. Relative strength versus SPY is -9.56 points over one month, a divergence that argues for caution until the price stabilizes.
  • Trailing margins are thin and volatile: Trailing net margin is just 10.97% and operating margin 17.24%, far below the Q3 quarterly figures, reflecting the weak Q4 2025 (net income of only $102 million) and the loss-making Q4 2024. ROE of 6.57% and ROA of 5.61% are modest for the sector and underscore how sensitive earnings are to crude prices.
  • Hold-heavy consensus, wide target spread: Despite the 'buy' headline, the recommendation mean of 2.29 leans closer to neutral, with 17 of 27 analysts at Hold. The $60.00 to $83.00 target range spans about 38% of the midpoint, signaling meaningful uncertainty about oil prices and the post-divestiture earnings base.

OXY Technical Analysis

OXY is in a choppy, range-bound consolidation rather than a clean trend: the stock is up 26.43% over the past year and 26.85% year-to-date, yet it sits at $53.76, only about 52.6% of the way through its 52-week range of $38.80 to $67.45. That positioning — solid annual gains but a price well below the highs — means the stock has given back a large share of its 2026 advance and is neither a momentum leader nor a washed-out value candidate. The 52-week high of $67.45 was set during the autumn rally, and the current price is roughly 20.3% below that peak, a drawdown consistent with the reported max drawdown of -27.63%.

Short-term momentum has deteriorated sharply and is diverging from the longer-term trend. The stock is down 14.29% over the past month and 12.61% over three months, versus a still-positive 26.43% one-year return, and it fell 4.88% on the latest session alone (from $56.52 to $53.76) on volume of about 13.0 million shares. Relative strength confirms the underperformance: -9.56 percentage points versus SPY over one month and -8.36 points over three months, even though the one-year relative strength remains a strong +15.81 points. This pattern — long-term outperformance eroding through a sharp short-term breakdown — typically signals either a mean-reversion pullback within an intact uptrend or the early stage of a trend reversal, and the heavy single-day decline argues for caution until the price stabilizes.

Key technical levels are well defined. Support sits at the 52-week low of $38.80, with the more relevant near-term floor being the July 2026 trough around $47.94; resistance is the 52-week high of $67.45, with the recent October peak near $64.17 as the first hurdle. A decisive break above $64-67 would confirm the uptrend has resumed and likely draw momentum buyers, while a break below the $48 area would validate the bearish divergence and open the door toward the $38.80 low. Notably, the reported beta of 0.149 implies very low sensitivity to the broader market, which is unusual for an E&P name and suggests OXY's risk is driven far more by oil prices and company-specific factors than by SPY — position sizing should be calibrated to commodity exposure rather than index beta.

Beta

0.15

0.15x market volatility

Max Drawdown

-27.6%

Largest decline past year

52-Week Range

$39-$67

Price range past year

Annual Return

+30.8%

Cumulative gain past year

PeriodOXY ReturnS&P 500
1m-14.0%-9.7%
3m-12.1%-9.9%
6m-8.3%-7.5%
1y+30.8%+4.7%
ytd+27.2%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

OXY Fundamental Analysis

Revenue is growing modestly but unevenly. Q3 2026 revenue of $6.772 billion was up 2.23% year over year versus $6.624 billion in Q3 2025, but the quarterly path has been volatile: $5.230 billion in Q1 2026, $8.327 billion in Q2 2026, and $6.772 billion in Q3 2026, reflecting both commodity price swings and the reshaping of the portfolio after the chemicals divestiture. The oil & gas segment generated $6.625 billion against $587 million from midstream, confirming that upstream production is the overwhelming driver of results. With consensus 2027 revenue estimated at about $25.33 billion (range $23.53-27.23 billion) and analysts flagging an expected roughly 32% profit drop next year, the growth trajectory looks like a cyclical plateau rather than structural expansion.

Profitability is strong at the operating line but noisy at the net line. Q3 2026 net income was $1.806 billion on a 26.67% net margin, with gross margin of 75.83%, operating margin of 33.40%, and EBITDA of $4.256 billion (62.85% EBITDA margin). The sequential trend is less flattering: Q2 2026 net income was $2.977 billion (35.75% net margin) and Q1 2026 was $3.345 billion, so earnings are compressing quarter over quarter as the price windfall fades. The trailing figures in the valuation dataset — net margin of 10.97%, operating margin of 17.24%, gross margin of 33.78% — are far below the Q3 quarterly margins, a gap that reflects the weak Q4 2025 (net income of just $102 million) and the loss-making Q4 2024, underscoring how sensitive earnings are to crude prices.

Balance-sheet health is improving and cash generation is solid. Debt-to-equity stands at 0.665, down from roughly 0.79 at the end of 2024, and Q3 2026 alone saw $1.819 billion of debt repayment; free cash flow was $2.415 billion in Q3 and $6.705 billion on a trailing basis, against operating cash flow of $3.672 billion. Liquidity is adequate but not generous, with a current ratio of 0.936 and $3.902 billion of cash at quarter-end, while ROE of 6.57% and ROA of 5.61% are modest for the sector. The dividend consumes $432 million per quarter (payout ratio of 67.3% on trailing earnings, 3.97% yield), and the combination of heavy capex ($1.257 billion in Q3) plus debt service means internal cash flow covers obligations but leaves limited cushion if oil prices fall further.

Quarterly Revenue

$6.8B

2026-09

Revenue YoY Growth

+2.2%

YoY Comparison

Gross Margin

75.8%

Latest Quarter

Free Cash Flow

$6.7B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Midstream Segment
Oil And Gas Segment

Open an Account, get $2 TSLA now!

Valuation Analysis: Is OXY Overvalued?

Because net income is positive, the PE ratio is the primary metric. OXY trades at 24.33x trailing earnings but only 10.31x forward earnings, a roughly 58% compression that implies the market expects a substantial earnings rebound — or, more precisely, that the trailing figure is depressed by weak prior quarters while forward estimates of $5.23 per share reflect a normalized oil price environment. The negative PEG ratio of -0.70 is not meaningful given the earnings volatility, and the 1.86x price-to-sales and 1.11x price-to-book multiples suggest the stock is not expensive on asset or revenue bases.

On peer comparison, OXY screens cheap relative to the broader market but roughly in line with E&P norms. Its 10.31x forward PE and 5.37x EV/EBITDA are consistent with a mature, commodity-exposed producer, while the 1.11x price-to-book is at a discount to the 1.3-1.9x range the stock has historically commanded. The 3.97% dividend yield is well above the sector average and reflects a payout that, at 67.3% of trailing earnings, is covered but not comfortably so. The discount to book and the high yield together suggest the market is pricing in commodity-price risk and the loss of the chemicals earnings stream rather than any structural impairment.

Historically, OXY's valuation has been volatile with the cycle: PE ranged from about 2.9x in Q1 2022 to over 38x in mid-2025, and price-to-book peaked near 2.13x in early 2022 before drifting down to the current 1.11x. The current book multiple sits near the low end of its multi-year band, which is consistent with either a value opportunity or a market judgment that returns on capital will remain subdued — the 6.57% ROE and 5.61% ROA support the latter interpretation. The forward PE of 10.31x versus a trailing 24.33x is the key signal: if the $5.23 consensus EPS materializes, the stock is inexpensive; if oil prices weaken and estimates are cut, the apparent cheapness evaporates.

PE

24.3x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 3x~22x

vs. Industry Avg

12.8x

Industry PE ~12.8x*

EV/EBITDA

5.4x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on earnings volatility and leverage. Quarterly net income collapsed from $3.345 billion in Q1 2026 to $1.806 billion in Q3, and trailing net margin of 10.97% versus Q3's 26.67% shows how violently results swing with crude prices — Q4 2025 produced just $102 million of net income and Q4 2024 was a $125 million loss. Debt-to-equity of 0.665 is improved but still heavier than many E&P peers, the current ratio of 0.936 is below 1.0, and the 67.3% payout ratio leaves limited room to sustain the $432 million quarterly dividend if cash flow weakens. With capex of $1.257 billion in Q3 and the chemicals earnings stream now sold, the company is more concentrated in upstream oil & gas, which generated $6.625 billion of Q3 revenue versus $587 million from midstream. Market and competitive risks are dominated by commodity price exposure and valuation compression. The Motley Fool noted the geopolitical supply shock has 'temporarily reversed revenue declines' but may accelerate demand destruction and the shift to alternatives, a direct threat to the windfall now fading. The beta of 0.149 implies very low market correlation, so OXY's drawdowns will be driven by oil rather than SPY — position sizing must be calibrated to commodity exposure. The forward PE of 10.31x versus trailing 24.33x embeds an earnings rebound; if 2027 estimates are cut toward the low end of the $4.75-$5.74 EPS range, the multiple expands and the stock de-rates. The worst-case scenario is a renewed oil price decline that forces estimate cuts, stalls deleveraging, and pressures the dividend. From $53.76, a retest of the July 2026 trough at $47.94 implies about -11%, while a move to the 52-week low of $38.80 implies roughly -28%, consistent with the -27.63% max drawdown already experienced. Even the analyst low target of $60.00 sits above the current price, so the realistic downside is defined by commodity prices rather than Street sentiment.

FAQ

The risk/reward is balanced rather than compelling at $53.76. On the positive side, the stock trades at 10.31x forward EPS versus 24.33x trailing, sits at 1.11x book against a historical 1.3-1.9x band, and the $71.11 average analyst target implies 32.3% upside with zero Sell ratings across 27 analysts. The downside is well mapped: a retest of the $47.94 July trough is about -11%, and the $38.80 52-week low is roughly -28%, consistent with the -27.63% max drawdown already experienced. However, 17 of 27 analysts sit at Hold with a 2.29 recommendation mean, and consensus models a ~32% profit decline in 2027, so the cheapness depends entirely on forward estimates being met. It is a reasonable buy for income-focused, value-oriented investors with a multi-year horizon who want a 3.97% yield and low 0.149 beta, ideally accumulating on stabilization above $48-50 rather than chasing a falling knife.